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Background
The main goal of the current study was to evaluate the
clinical tolerance of a modified dust mite subcutaneous
extract in a small subset of severe extrinsic asthmatic
subjects.
Methods
We selected 3 adult patients with a confirmed diagnosis of
severe persistent allergic asthma (ATS criteria for severe
asthma) for at least five years. Mean average topical steroid
(inhaled) daily dose was above 1000 mcg of fluticasone
propionate or 1600 mcg of budesonide. All patients
included in the current trial were clinically relevant sensi-
tized to dust mites (Dermatophagoides spp.) as shown by
skin prick test and/or specific IgE. Inclusion criteria
required no hospital or emergency admissions for the last
2 months with no changes in their daily medication in the
last four weeks prior to the administration of immu-
notherapy. No pre-treatment with systemic steroids and/
or antihistaminics were used. Modified standardized speci-
fic dust mites immunotherapy extracts were subcuta-
neously administered according to a validated protocol to
achieve a final dose of 100 DDP/ml in a two-week cluster
schedule. None of the subjects in both groups have been
previously treated with omalizumab. Clinical observation
and lung function was strictly monitored in all subjects
until the maintenance dose of immunotherapy was
reached.
Results
The three patients could reach the proposed allergen
dose according to the immunotherapy schedule in two
weeks. No significant adverse reactions were recorded,
with no changes in the lung function. Minor immediate
local reactions at the injections site were only observed
at the maximal allergen dose in 2 patients showing a
good response to oral antihistaminics in all cases. No
late adverse reactions were present.
Conclusion
The standardized specific allergen immunotherapy dose
was successfully reached in a small group of severe persis-
tent allergic asthmatics. Further studies are needed to eval-
uate the role of specific immunotherapy in controlled
severe allergic asthma.
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